Inspire Investing LLC Takes Position in Smith & Nephew SNATS, Inc. $SNN

Key Points

• Inspire Investing LLC acquired a new stake in Smith & Nephew SNATS, Inc., purchasing 7,273 shares valued at approximately $223,000 in the second quarter.
• Analysts have mixed ratings for SNN, with Canaccord Genuity raising the target price to $36.00 while Wall Street Zen downgraded it from "strong-buy" to "buy."
• Smith & Nephew recently declared a semi-annual dividend of $0.285, with a dividend payout ratio of 26.39% and an impressive yield of 165.0% due to its recent performance.

Inspire Investing LLC purchased a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 7,273 shares of the medical equipment provider's stock, valued at approximately $223,000.

Other large investors have also recently modified their holdings of the company. Hexagon Capital Partners LLC grew its stake in shares of Smith & Nephew SNATS by 63.3% in the first quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 406 shares during the last quarter. Richards Merrill & Peterson Inc. raised its position in Smith & Nephew SNATS by 500.0% in the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider's stock worth $34,000 after acquiring an additional 1,000 shares during the period. Bessemer Group Inc. increased its stake in shares of Smith & Nephew SNATS by 3,471.4% in the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after purchasing an additional 1,701 shares in the last quarter. Banque Transatlantique SA bought a new stake in shares of Smith & Nephew SNATS during the first quarter valued at approximately $52,000. Finally, GAMMA Investing LLC grew its stake in shares of Smith & Nephew SNATS by 22.4% in the 1st quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock worth $103,000 after buying an additional 666 shares in the last quarter. Hedge funds and other institutional investors own 25.64% of the company's stock.

Analyst Ratings Changes

SNN has been the subject of several research analyst reports. Canaccord Genuity Group lifted their target price on Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a "hold" rating in a research report on Monday, August 18th. Wall Street Zen downgraded shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a report on Friday, October 3rd. Weiss Ratings reissued a "hold (c+)" rating on shares of Smith & Nephew SNATS in a research note on Wednesday, October 8th. Finally, Sanford C. Bernstein set a $37.50 price target on shares of Smith & Nephew SNATS and gave the company a "market perform" rating in a research note on Tuesday. Eight analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Smith & Nephew SNATS currently has an average rating of "Hold" and a consensus target price of $36.75.

Smith & Nephew SNATS Stock Up 1.5%

Shares of NYSE SNN opened at $36.35 on Friday. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $38.79. The firm's 50 day moving average price is $36.71 and its 200 day moving average price is $31.70. The firm has a market cap of $15.51 billion, a P/E ratio of 16.83, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.40 and a current ratio of 3.00.

Smith & Nephew SNATS Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be issued a $0.285 dividend. The ex-dividend date is Friday, October 3rd. This represents a yield of 165.0%. Smith & Nephew SNATS's dividend payout ratio (DPR) is presently 26.39%.

About Smith & Nephew SNATS

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.